Phase 3 Bladder Cancer Trial, Recruiting NCT06651697 Sponsor: University of California, San Diego Condition: Bladder Cancer
Back to Bladder Cancer

Phase 3 Bladder Cancer Trial, Recruiting

NCT06651697
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have signed and dated a consent form agreeing to take part in the study
  • People who are willing and available to follow all study procedures for the full duration of the trial
  • People whose doctors have determined them suitable to receive radiation therapy aimed at curing a cancer of the pelvis, including urinary (GU), bowel/digestive (GI), or gynaecological (Gyn) cancers
  • People who are able to become pregnant and have used highly effective contraception for at least one month before screening, with agreement to continue doing so during the study
  • People who are able to cause a pregnancy and agree to use condoms or other effective contraception with their partner during the study

Who may not be able to join:

  • People who are currently pregnant
  • People whose cancer has grown into the bladder, as determined by the enrolling doctor based on available medical information
  • People who have medical conditions that make radiation therapy unsafe, including Crohn's disease, or active connective tissue disorders such as scleroderma or lupus that is not well controlled
  • People who have previously received radiation therapy to the same area of the body that would need to be treated in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tyler Seibert, MD, PhD, University of California, San Diego

Phone: 858 822 5354

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 November 2024
Est. completion
1 April 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Acute toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov